Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) has declared that its subsidiary, Xuanzhu Biopharmaceutical Co., Ltd, has entered into a licensing agreement with fellow pharmaceutical company Livzon Pharmaceutical Group Inc. (HKG: 1513) for the development and commercialization of fadanafil, a Category 1 chemical compound. Under the terms of the agreement, Livzon has been granted exclusive rights to develop, manufacture, and commercialize the drug in Greater China and select non-standard market regions. Conversely, Xuanzhu will maintain the rights to develop and commercialize fadanafil in Europe, the US, Canada, Japan, South Korea, Australia, and Brazil. As part of the deal, Livzon will make an undisclosed upfront payment to Xuanzhu and is also obligated to pay milestone fees and royalties based on future sales.
Fadanafil is a selective phosphodiesterase 5 (PDE5) inhibitor with potential applications in treating prostate hyperplasia and associated lower urinary tract symptoms, as well as erectile dysfunction and pulmonary hypertension. It is designed to avoid adverse reactions such as visual impairment and back pain that can be associated with other PDE5 inhibitors like sildenafil, vardenafil, and tadalafil. The compound is currently undergoing Phase I clinical trials.- Flcube.com
